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Clinical Experience with ALG 
T. E. STARZL, M. D., PH. D., CHARLES, W. PUTNAM, M. D. 
University of Colorado, Medical Center, Dept. Surgery; Denver, Colorado, USA 
There will be little point in dwelling on our 
clinical experience with ALG, extensive though 
this has been. The reason is that we have not 
carried out a contemporaneous control study 
omitting ALG. We do not have, as a conse-
quence, proof that our results were improved 
by the clinical introduction of ALG. Never-
theless, there is evidence supporting this point 
of view which we will briefly describe. 
Related Transplantations 
Our first renal homotransplantations were car-
ried out in 1962. If related donors could be 
found, substantial benefits for the majority of 
recipients were obtained from the very be-
ginning of our experience. 
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Fig. 1 
Life survival curves of 3 groups of recIpients of 
consanguineous kidneys. The patients in Series I 
were treated with the double drug program of 
azathioprine and prednisone from 1962 to March, 
1964 and, consequently, have potential follow-ups 
of 8 to 91/2 years. The patients of Series II were 
treated from October, 1964 to April, 1966 and, 
consequently, have potential follow-ups of 6 to 
71/2 years. They received the same drug therapy as 
in Series I and, in addition, an attempt was made 
at donor selection by HL-A matching. The recipients 
of Series III were treated with the triple drug 
program of azathioprine, prednisone, and ALG 
between June, 1966 and April, 1968; they have 
potential follow-ups of 4 to 6 years. In all 3 series, 
the denominator indicates the surviving patients 
whereas the numerator tells the number of originally 
transplanted kidneys that are still functioning in 
those survivors. 
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In Fig. 1 is shown graphically the fate of 131 
consecutive patients who were given kidneys 
by siblings, parents, or more distantly related 
donors such as aunts, uncles or cousins between 
1962 and the spring of 1968. The follow-up 
in Series I is now 8 to 9112 years, in Series II 
from 6 to 71/2 years, and in Series III from 
4 to 6 years. 
The 71 patients of Series I and II were treated 
with azathioprine and prednisone. Tissue typing 
techniques were not used in Series I since 
they were not yet available. In Series II, an 
effort was made by Dr. P. Terasaki to select 
the best donor amongst those available in any 
given case. This effort of donor discrimination 
was not beneficial (Fig. 1) and, in fact, the 
eventual survival was somewhat inferior to 
that in Series 1. 
The 60 patients of Series III were administered 
horse antilymphocyte globulin (ALG) in addi-
tion to azathioprine and prednisone. With 
minimum of follow-ups of at least 4 years, 
the survival of both patients and grafts appears 
to have been increased (Fig. 1). Even today, 
after 4 to 6 years, 75 010 of these ALG treated 
patients are still alive and all but 3 of the 
survivors (42 of 45) have acceptable function 
of their original homografl:s. 
Generally, the ALG treated patients had glob-
ulin therapy for about 4 months post-transplan-
tation, with intramuscular injections of 3 to 
6 mg/kg. The ALG was started several days 
before operation and given daily for 2 weeks, 
every other day for 2 weeks, twice a week 
for 2 months and once a week for a final 
month. Because they were the only available 
source of human lymphoid tissue in large 
quantities, human spleens were used in this 
era to raise the ALG with careful attention 
being paid to separating the leukocytes from 
stroma, platelets and red cells before their 
inoculation into horses. After absorption and 
purification the eventual product usually had 
lymphocytotoxic and leukoagglutinin titers of 
1 : 4000 or preferably greater. Anti-GBM 
activity was not demonstrable in the Dixon rat 
model. 
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The results after transplantation of non-related 
kidneys. The conditions of treatment and the 
meaning of the figures in the parenthesis are identi-
cal to those in Fig. 1. Note that the results with 
non-related kidneys have been inferior to those 
with related grafts at all levels of our experience. 
The follow-ups are also the same as in Fig. 1 except 
in Series III, in which the potential follow-ups are 
3 to 6 years. 
Non-Related Homografts 
As with the consanguineous cases, the intro-
duction of ALG as part of a triple drug 
treatment program was associated with an 
improvement in results. This is demonstrated 
in Fig. 2, ill which Series I and II conform to 
the same intervals defined in the preceding 
section, and in which Series III is also com-
parable except that cases were included 
through April, 1969. In the 1962-1966 era, 
the patient survival rate at one year was bet-
ween 33 and 52010. In Series III, this one 
year figure rose to 82 Ofo (14 of 17 patients). 
After one year, in all 3 series, including the 
final ALG group, the ultimate survival has 
drilled off far more rapidly than with the use 
of related homografts. 
Is There an Indispensable Drug? 
Subsequent to the completion of Series III, 
and continuing until February, 1971, more 
than 160 additional patients were given either 
related or cadaveric renal homogralls under 
immunosuppressive therapy with azathioprine, 
prednisone, and ALG. In a general way, the 
results were confirmatory of those in Series III, 
although the survival was not quite so high, 
primarily because the medical criteria for ac-
ceptance to the program were so drastically 
relaxed. Finally, for more than a year cyclo-
phosphamide has been used in place of azathio-
prine in a triple drug program that includes 
steroids and ALG. Here, too, the results have 
been good, both in related and non-related 
cases. 
In reviewing our experience of the last decade 
as we have just briefly done, the point can be 
made that the one absolutely indispensable 
agent that has made renal transplantatio~ 
practica:! i:s ·"prednisone. More than occasional 
successes are possible with the omission of 
either one or 2 of the three other major agents 
we have mentioned, namely azathioprine, 
cyclophosphamide or ALG. However, without 
adrenal corticosteroids, we believe that the 
management and reversal of rejection would 
be so seldom achievable that the clinical disci-
pline of renal transplantation would vanish. 
It is in this context that ALG must be evaluat-
ed. We have always considered ALG to be an 
adjuvant immunosuppressant, and one which 
is of the greatest value for short-term use 
during the ollen difficult early postoperative 
period when the issue of gratl; acceptance or 
failure is most commonly decided. When used 
in this way, rather than as a panacea, we have 
been convinced that ALG is an important part 
of our therapeutic armamentarium and one 
that has not only improved survival but also 
the quality of convalescence. Improvements in 
the raising and standardizing of our ALG have 
been described at another session by Dr. 
C. Groth; (this issue; page 86). 
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